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a  b  s  t r  a  c  t
Human  hepatitis  B virus  (HBV)  core  antigen  (HBcAg)  can act as  an  adjuvant  in  hepatitis  C  virus  (HCV)-
based  DNA  vaccines.  Since  two billion  people  are,  or have  been,  in contact  with  HBV,  one may  question
the  use  of  human  HBV  sequences  as  adjuvant.  We  herein  evaluated  non-human  stork  hepatitis  B virus
core  gene-sequences  from  stork  as DNA  vaccine  adjuvants.  Full-length  and  fragmented  stork  HBcAg  gene-
sequences were  added  to an HCV  non-structural  (NS)  3/4A  gene  (NS3/4A-stork-HBcAg).  This  resulted  in
an enhanced  priming  of HCV-speciﬁc  IFN-  and  IL-2  responses  in  both  wild-type  (wt)- and  NS3/4A-
transgenic  (Tg)  mice,  the  latter  with  dysfunctional  NS3/4A-speciﬁc  T cells.  The  NS3/4A-stork-HBcAg
vaccine  primed  NS3/4A-speciﬁc  T  cells  in  hepatitis  B e antigen  (HBeAg)-Tg  mice  with  dysfunctional  T
cells  to HBcAg  and  HBeAg.  Repeated  immunizations  boosted  expansion  of  IFN-  and  IL-2-producinglectroporation
elivery
djuvant
NS3/4A-speciﬁc  T cells  in  wt- and  NS3/4A-Tg  mice.  Importantly,  NS3/4A-stork-HBcAg-DNA  induced
in  vivo  long-term  functional  memory  T cell  responses,  whose  maintenance  required  CD4+ T  cells.  Thus,
avian  HBcAg  gene-sequences  from  stork  can  effectively  act  as  a DNA  vaccine  adjuvant.  This  technology  can
most likely  be universally  expanded  to  other  genetic  vaccine  antigens,  as  this  completely  avoids  the  use
of sequences  from  a  human  virus  where  a pre-existing  immunity  may  interfere  with  its adjuvant  effect.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-ND. Introduction
Chronic hepatitis C virus (HCV) infection is a major causative
gent for severe liver disease and cancer worldwide. Globally,
round 185 million individuals are estimated to have anti-HCV
ntibodies and of these 130–170 millions are chronic carriers of the
irus [1,2]. Importantly, this infection is today considered curable
n the majority of individuals receiving the recently introduced
irect-acting antiviral (DAA) therapy [3–7]. Therefore the urgency
or a HCV vaccine has reduced. However, only 10% of all chronic
CV carriers receive any treatment [1] due to high cost of treat-
ent and the majority of the chronic carriers live in resource-poor
ountries. Hence, there is still an urgent need to prevent the spread
f HCV through a vaccine. Today, no prophylactic or therapeutic
accines are available. However, numerous vaccines have been
eveloped and tested for efﬁcacy in clinical trials [8–14]. A few
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HCV vaccines are currently being tested for both protective and
therapeutic effects [15–17].
A key feature of patients with chronic HCV is their lack of func-
tional T cell responses to HCV [18–23]. Interestingly, a recent study
showed that DAA induced cure of HCV rapidly restores at least
partly HCV-speciﬁc T cell responses [24]. However, these responses
do not seem to protect against re-infection [25]. Thus, a therapeu-
tic HCV vaccine would be of importance to support eradication of
HCV infection and to broaden the HCV post-cure T cell response
to reduce the risk of re-infection. On the other hand, a prophylac-
tic HCV vaccine would instead be crucial in reducing the risk of
acquiring HCV, especially since the majority of HCV infected indi-
viduals develop an asymptomatic chronic infection that is often
ﬁrst diagnosed at a late stage of the liver disease. A functional pro-
phylactic and/or therapeutic HCV vaccine will save signiﬁcant costs
and reduce HCV associated morbidity and mortality.
We  have previously shown that the addition of heterologous
gene sequences makes antigen-speciﬁc vaccines more effective in
the presence of dysfunctional antigen-speciﬁc T cell responses [26].
The human hepatitis B core antigen (HBcAg) is a potent molecular
adjuvant both as a protein and in genetic vaccines [26–28]. How-
ever, since two billion people have been in contact with HBV, one
may  question the use of human HBV sequences as adjuvant. We
 under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/
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herefore here exploit the use of avian HBcAg sequences as het-
rologous adjuvant sequences. Notably, human and avian HBcAg
how less than 40% amino acid sequence homology and they do
ot share the same HLA/MHC class I and II epitope sequences.
erein, the avian HBcAg adjuvant sequences were evaluated using
ur previously clinically evaluated genotype 1 HCV non-structural
/4A (NS3/4A) based genetic vaccine [8,29,30]. We  found that avian
BcAg gene sequences signiﬁcantly improved the DNA-based HCV
accine.
. Methods
.1. Animals
Inbred female C57BL/6J (H-2b), CD4-deﬁcient (e.g. CD4−/− (H-
b)), CD8-deﬁcient (e.g. CD8−/− (H-2b)), C57BL/6J mice transgenic
Tg) for full-length wild-type HCV nonstructural (NS)3/4A of geno-
ype 1a (NS3/4A-Tg) under the control of the mouse major urinary
rotein promoter (MUP) [31], and C57BL/6J mice transgenic for
BeAg subtype ayw under the control of the metallothionein
romoter (HBeAg-Tg) [27,32–34], were housed at Karolinska Insti-
utet, Division of Comparative Medicine, Clinical Research Center,
arolinska University Hospital, Huddinge, Sweden. The NS3/4A-Tg
nd the HBeAg-Tg mouse models were used to assess vaccine-
rimed immune responses because they better represents a model
f an infected host with dysfunctional T cell responses to NS3/4A
NS3/4A-Tg) or to both HBcAg and HBeAg (HBeAg-Tg). Vaccine eval-
ation in wild-type mice will only address naïve immune responses
nd is therefore less relevant for studies of chronic infections.
he animals were either purchased (Charles River Laboratories,
ulzfeld, Germany and the Jackson Laboratory, Bar Harbor, ME)  or
red in-house. The animals were caged at ﬁve to ten mice per cage
nd fed with a commercial diet (RM3 (p) PL IRR diet; Special Diet
ervice) with free access to food and water. All animals were six
o ten weeks of age at the start of the experiment. All NS3/4A-Tg
ice were genotyped by PCR to verify the transgene. Extraction
f DNA from the tail was performed using the DNeasy Blood and
issue Kit (Qiagen, Hilden, Germany), according to the manufac-
urer’s instructions, and the NS3/4A transgene and the reference
ene tubulin were ampliﬁed by PCR. All experimental protocols
nvolving animals were approved by the Ethical Committee for Ani-
al  Research at Karolinska Institutet. The methods were carried out
n accordance with the approved guidelines.
.2. Plasmid DNA
The codon-optimized (co) NS3/4A-pVAX1 genotype 1a plasmid
GenBank accession number: ncbi-n:AR820945.1; http://www.
bci.nlm.nih.gov/genbank) has been described previously [30,35].
n addition, ﬁve codon-optimized fusion constructs of NS3/4A and
tork HBcAg (co-Stork-HBcAg) were made synthetically (Retro-
en, San Diego, CA and Genscript, Piscataway, NJ) and inserted
nto the pVAX1 vector (Invitrogen, Carlsbad, CA) (Fig. 1c). The ﬁve
eparate fusion constructs were made with the following modiﬁ-
ations: C2.1 (GenBank accession number: ncbi-n:GZ869905.1), a
oNS3/4A-coStork-HBcAg fusion construct (active protease) con-
aining an NS3-NS4A cleavage site between NS3 and NS4A and
n NS4A-NS4B cleavage site between NS4A and stork-HBcAg.
S3, NS4A, and stork-HBcAg are separated by NS3/4A proteolytic
leavage. The C2.3 construct (GenBank accession number: ncbi-
:GZ869907.1) is identical to C2.1 but with an inactive “mutated”
CV NS3 protease and the NS3-NS4A and NS4A-NS4B cleavage sites
ave been replaced with 2A self-cleaving peptide sequences. The
2.2 (GenBank accession number: ncbi-n:GZ869906.1), C2.4 (Gen-
ank accession number: ncbi-n:GZ869908.1), and C2.5 (GenBank
ccession number: ncbi-n:GZ869909.1) constructs are identical to4 (2016) 2821–2833
C2.1 and C.2.3, but contain coStork-HBcAg modiﬁcations consist-
ing of the introduction of three NS3-NS4A cleavage sites (C2.2
and C2.5, e.g. constructs contain an active protease) or 2A self-
cleaving peptide sites (C2.4, e.g. has an inactive “mutated” HCV
NS3 protease) in the coStork-HBcAg gene sequence, allowing the
expressed NS3/4A protease or the 2A peptide to cleave the modi-
ﬁed Stork-HBcAg into four parts (Stork-HBcAg: aa 1–66, aa 67–132,
aa 133–198, and aa 199–264). In the C2.5 construct the orienta-
tion of the Stork-HBcAg is as follows: aa 199–264, aa 133–198, aa
1–66, and aa 67–132. The C8 construct (GenBank accession num-
ber: ncbi-n:GZ869918.1) is identical to the C2.5 but contain human
HBcAg as described previously [26]. Additional constructs used
within this study; wtNS3-pVAX1 [35] (GenBank accession number:
ncbi-p:AFS93973.1), wtNS3/4A pVAX1 [30,35] (GenBank accession
number: ncbi-n:GZ869870.1), coHBcAg-pVAX1 [28,36] (GenBank
accession number: ncbi-n:DI244925.1), wt- and co-Stork-HBcAg-
pVAX1 (GenBank accession number: ncbi-n:GZ869879.1), and wt-
and co-Heron-HBcAg-pVAX1 (GenBank accession number: ncbi-
n:GZ869880.1).
Mouse interleukin-12 (pORF-mIL-12, mIL-12) was  purchased
from InvivoGen (San Diego, USA). Plasmids were grown in com-
petent TOP10 Escherichia coli (Life Technologies, Carlsbad, CA) and
puriﬁed using Qiagen EndoFree Plasmid puriﬁcation Kit according
to the manufacturer’s instructions (Qiagen, Hilden, Germany). Plas-
mid  DNA concentration was determined spectrophotometrically
and the puriﬁed DNA was  dissolved in sterile PBS at concentrations
of 2 mg/ml. Restriction enzyme digest were performed to ensure
that the plasmid contained the gene of interest with the correct
size. All DNA plasmids were sequenced to ensure correct nucleotide
sequence (Euroﬁns MWG  Operon, Ebersberg, Germany).
2.3. In vitro transcription and translation assay
To conﬁrm expression and proteolytic/self-cleaving activity of
the studied constructs an in vitro transcription and translation assay
(TNT; Promega, Madison, WI)  were employed [30,37].
2.4. Cell line
HepG2 was maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum (FBS) (Sigma–Aldrich,
St. Louis, MO), 2 mM  l-glutamine, 10 mM HEPES, 100 U ml−1 peni-
cillin, 100 g/ml streptomycin, 1 mM nonessential amino acids, and
1 mM sodium pyruvate (Sigma–Aldrich). The cells were grown in a
humidiﬁed 37 ◦C and 5% CO2 incubator.
2.5. Transient transfection, protein sample preparation,
immuno-precipitation and Western blot analysis
HepG2 cells were transiently transfected using TurboFect
(Fermentas, Leon-Rot, Germany), according to manufacturer’s
instructions. In brief, 1 × 106 cells per 25 cm2 (e.g. T25) ﬂask were
transiently transfected using 4 g plasmid DNA together with 6 l
TurboFect in vitro transfection reagent and incubated for 36 h prior
to harvest. Cells were harvested and lysed in 1 ml  RIPA buffer
(0.15 mol/L NaCl containing 50 mmol/L Tris, 1% Triton X-100, 1% Na-
deoxycholate, and 1% SDS). Liver biopsies (100 mg) were homoge-
nized using sonication (Vibra Cell Homogenizator; Chemical Instru-
ments, Lidingö, Sweden) in 1 ml  RIPA buffer. The liver homogenates
were incubated on ice for 10–20 min  and centrifuged at 12,000 × g
for 2 min  at 4 ◦C, and the supernatant was  transferred to a new
vial and stored at −80 ◦C until analysis. The cell and liver lysates
were immuno-precipitated with protein-A sepharose and poly-
clonal mouse anti-NS3 antibody overnight at 4 ◦C. Samples were
diluted in SDS sample buffer, heated at 100 ◦C for 5 min  before SDS-
PAGE analysis on 4–12% Bis-Tris gel (Life Technologies, Carlsbad,
CA) followed by electrotransfer onto nitrocellulose membranes
S. Levander et al. / Vaccine 34 (2016) 2821–2833 2823
Fig. 1. Humoral immunogenicity of heron and stork HBcAg genes and design and expression of NS3/4A-HBcAg fusion genes. The polymorphism of stork and human HBcAg
epitopes are shown for two published HLA-A2.1 epitopes (HBc18-27 [56] and HBc141-149 [57]) and two H-2b epitopes (HBc93-100 [39] and HBc129-140 [40]) (a). An
“-”  indicate epitope sequences homology. Groups of ﬁve wild-type C57BL/6J mice were immunized twice intramuscularly with 100 g of Stork-, Heron- or human HBcAg
plasmid  DNA and anti-HBc IgG titers determined at indicated time-points (b). Also, mice were immunized intramuscularly using wild-type- or codon-optimized Stork-HBcAg
plasmids with or without in vivo ET. Groups were compared by serum dilution and measurement of optical density at 450 nm.  Design of the coNS3/4A-coHBcAg containing
DNA  constructs evaluated in the present study (c). The plasmids encode codon-optimized HCV NS3 and NS4A proteins followed by different variants of HBcAg either derived
from  stork or human. An “empty triangle” indicates a HCV NS3 protease cleavage site whereas a “ﬁlled triangle” describes a self-cleaving 2A peptide sequence. In constructs
containing self-cleaving sequences the NS3 protease has been inactivated by mutation of amino acids in the catalytic triade. Numbers (e.g. 1–4) indicated in the constructs
containing fragmented HBcAg sequences refers to the order of the different fragments in the gene sequence. Individual wild-type (wt) NS3, wtNS3/4A, coNS3/4A, coHBcAg
constructs and fusion constructs (C2.1–C2.5) were tested for their expression by an in vitro transcription and translation assay (d), and/or by transient transfection of HepG2
cells  (e). NS3-protein expression was determined by immune-precipitation and Western blot (d). M indicates the molecular weight marker, Magic Mark (Life Technologies,
Carlsbad, CA). IgH = immunoglobulin heavy chain.
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sing the iBlot (Life Technologies, Carlsbad, CA). NS3-proteins were
etected using a polyclonal mouse anti-NS3 antibody (diluted
:100). Chemiluminescence-linked Western blot kit (Western-
reeze WB7104, anti-mouse; Life Technologies, Carlsbad, CA) was
sed for the detection of NS3 according to the manufacturer’s pro-
ocol. Chemiluminescent signals were detected using the G:BOX
hemi XX6 gel documentation system (Syngene, Cambridge, UK).
.6. Peptides and proteins
A total of 135 15-mer peptides (each having 10 amino acid
aa) overlap) covering the full-length HCV NS3 and NS4A geno-
ype 1a protein were purchased from Sigma–Aldrich (St. Louis,
O). The 135 peptides were divided into nine peptide pools as
utlined: pool 11026–1110, pool 21101–1185, pool 31176–1260, pool
1251–1335, pool 51326–1410, pool 61401–1485, pool 71476–1560, pool
1551–1635, and pool 91626–1710. In order to perform detailed stud-
es of HCV- and HBV-speciﬁc CD4+ and CD8+ T cell responses,
reviously identiﬁed H-2b-restricted CTL and T helper (Th) epi-
opes were used: HCV NS3-CTL peptide (H2-Db aa sequence:
AVQNEVTL (NS3 aa 1629–1637)) [35], HCV NS3-Th peptide (aa
equence: EIPFYGKAIPLEAIK (E13K aa 1372–1386)) [38], HBcAg-
TL peptide (H-2Kb aa sequence: MGLKFRQL (HBcAg aa 93–100))
39], and HBcAg-Th peptide (H-2IAb aa sequence: PPAYRPPNAPIL
HBcAg aa 129–140)) [40]. The following non-HBV control peptides
ere used; SIINFEKL (OVA 257–264, CTL-epitope) and ISQAVHAA-
AEINEAGR (OVA 323–339, Th-epitope) were synthesized by
utomated peptide synthesis as described previously (ChronTech
harma AB, Huddinge, Sweden) [41]. Recombinant HCV NS3 pro-
ein gt1a (aa 1207–1612) and HBcAg-protein (aa 1–183) were
roduced in E. coli and puriﬁed as described [42]. Chicken egg
lbumin (OVA) and Concanavalin A (ConA) were purchased from
igma–Aldrich (St. Louis, MO).
.7. Immunization protocol
Groups (5–10 mice/group) of female C57BL/6J (wt), CD4−/−,
D8−/−, NS3/4A-Tg, and HBeAg-Tg C57BL/6J mice, 6–10 weeks
ld, were immunized intramuscularly (i.m.) in the tibialis cra-
ialis muscle one to ﬁve times with doses of 50, 5, 0.5, 0.05, and
.005 g plasmid DNA (e.g. coNS3/4A-pVAX1, C8-pVAX1, C2.1-
VAX1, C2.2-pVAX1, C2.3-pVAX1, C2.4, and C2.5-pVAX1) alone or
n combination with 5 g mIL-12-pORF1 in a volume of 30 L
sing the in vivo intracellular injection device (IVIN) [27,43] or
y regular needle injection. Immediately following administration
f the plasmid DNA, tibialis cranialis muscles were subsequently
lectroporated (EP) using the Cliniporator2 device (IGEA, Carpi,
taly) with a 1 ms  600 V/cm pulse followed by a 400 ms  60 V/cm
ulse pattern. Mice were boosted at monthly intervals. A detailed
escription of the IVIN device, used for delivery of DNA vaccine, is
escribed previously [43]. Analysis of HCV NS3/4A-speciﬁc immune
esponses were performed at two-weeks or six months post last
mmunization. Determination of HCV NS3-protein expressing liver
ells in vivo was performed in groups of immunized and non-
mmunized mice. Six months after the last immunization, mice
ere given a hydrodynamic injection of the coNS3/4A plasmid,
xactly as described previously [44]. In brief, a total volume of
.8 ml  (8% of body weight) Ringers solution containing 100 g
oNS3/4A-pVAX1 was injected intravenously in the tail vein within
 s. Presence of HCV NS3-protein expression was determined 72 h
ater by immune-precipitation and Western blot analysis.
.8. Detection of HBcAg-speciﬁc antibodies using ELISASerum from immunized C57BL/6J mice were collected at week
, 4, and 6 via retro-orbital bleeding of Isoﬂuran anesthetized mice.
etection of mouse IgG antibodies to HBcAg was performed as4 (2016) 2821–2833
described previously [45]. In brief, plates were coated with 2 g/ml
HBcAg protein. Mouse serum was added in serial dilution (starting
dilution of 1:50 and then diluted 1:5). OD was read at 405 nm with
a 620 nm background. The cutoff value was  set to three times the
OD value of negative serum sample.
2.9. Detection of IFN-- and IL-2-producing CTLs and Th cells by
ELISpot assay
Splenocytes from groups of mice (5–10 mice/group) were
pooled and tested for the presence of NS3/4A- or HBcAg-speciﬁc
T cells. We  assessed the ability of NS3/4A- and HBcAg-speciﬁc CTLs
and Th cells to produce IFN- and IL-2 after exposure to differ-
ent peptides and proteins: NS3-CTL gt1a (GAVQNEVTL), NS3-Th
E13K gt1a (EIPFYGKAIPLEAIK), HBcAg-CTL (MGLKFRQL), HBcAg-Th
(PPAYRPPNAPIL), recombinant HCV NS3 and HBcAg proteins. The
following non-HCV and HBV peptides and proteins were included
as control antigens: OVA-CTL (SIINFEKL), OVA-Th (ISQAVHAA-
HAEINEAGR), and OVA protein (OVA grade VII). Concanavalin A
was used as a positive control and DMSO at the same concentra-
tion as in the peptide pools were used as a negative control and/or
medium alone. Production of IFN- and IL-2 cytokines was deter-
mined by a commercially available ELISpot assay (Mabtech, Nacka
Strand, Sweden) exactly as described previously [46]. The number
of spots was  counted using the AID iSpot reader and software ver-
sion 7.0 (AID, Strassberg, Germany). The number of spots (cytokine
producing cells) was determined at each concentration of peptide
or protein and the results given as the number of IFN- or IL-2-
producing cells per 106 cells. A mean number of cytokine producing
cells of 50 per 106 cells were considered as negative.
2.10. Quantiﬁcation of HCV NS3- and HBcAg-speciﬁc CD8+ T cells
by pentamer staining
The frequency of NS3- and HBcAg-speciﬁc CD8+ T cells was
analyzed by direct ex vivo staining of splenocytes using the NS3
GAVQNEVTL (H2-Db) and HBcAg MGLKFRQL (H-2Kb) Pro5 pen-
tamers (ProImmune, Oxford, U.K.) performed exactly as described
previously [26]. The following antibodies were used: anti-mouse
CD16/32 “Fc block”, anti-mouse CD19-APC “clone 1D3” (BD
Biosciences, San Jose, CA), anti-mouse CD8-FITC “clone KT15”
(ProImmune). A total of 150,000 total events from each sample
were acquired on a FACSCalibur or FACSVerse ﬂow cytometer (BD
Biosciences) and analyzed using the CellQuest (San Jose, CA) or
FlowJo 9.2 software (Ashland, OR).
2.11. Statistical analysis
All comparisons were performed using GraphPad InStat 3, Mac-
intosh (version 3.0b, 2003; GraphPad Software, San Diego, CA)
and Microsoft Excel 2011, Macintosh (version 14.3.9; Microsoft,
Redmond, WA). Kinetic measurements were compared using the
area under the curve (AUC, Excel). Parametrical data were com-
pared using the analysis of variance (ANOVA) and non-parametrical
data with Mann–Whitney U test. Frequencies were compared using
Fisher’s exact test.
3. Results
3.1. Immunogenicity of heron and stork HBcAg genes
We  have previously shown that inclusion of the human hepati-
tis B virus core antigen (HBcAg) improves the immunogenicity of
HCV NS3/4A-based genetic vaccines [26]. As HBV is a common virus
and many individuals may  have a pre-existing immunity to HBV
antigens, including HBcAg, HBV sequences from another species
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hould be safer [47]. In particular avian hepadnaviruses, such as
he duck (DHBV), heron (HHBV), and stork (STHBV) hepatitis B virus
re genetically distant from human HBV [48]. Amino acid sequence
lignment of full-length stork and human HBcAg proteins revealed
ess than 40% sequence homologue. A detailed analysis of two  pub-
ished HLA-A2.1 epitopes and two H-2b epitopes further indicate
o evident epitope sequence homology between stork and human
BcAg (Fig. 1a).
We  ﬁrst evaluated the intrinsic immunogenicity of wild-type
BcAg sequences from heron and stork (Fig. 1b). Both heron and
tork HBcAg DNA plasmids induced similar levels of antigen-
peciﬁc IgG antibodies as human HBcAg (Fig. 1b). We  then
ested whether the immunogenicity of stork HBcAg-DNA could be
mproved by codon-optimization (co) and in vivo electro transfer
ET; Fig. 1b). Both these parameters clearly improved immuno-
enicity (Fig. 1b).
.2. Generation of NS3/4A and stork HBcAg fusion genes
We  now wanted to test if we could transfer the potent immuno-
enicity of stork HBcAg to function as an adjuvant for HCV NS3/4A,
s we previously found that human HBcAg could [26]. To under-
tand the adjuvant effect of stork HBcAg on HCV NS3/4A we
esigned and tested constructs with the same design as previously
valuated using human HBcAg and HCV NS3/4A [26]. We  generated
usion genes expressing HCV NS3/4A and full-length or fragmented
tork HBcAg proteins (Fig. 1c). The fragmented HBcAg sequences
ontained either NS3/4A cleavage sites or self-cleaving 2A peptide
equences between and/or within the expressed proteins (Fig. 1c)
49,50]. The NS3 protease function was abolished in constructs con-
aining self-cleaving 2A peptide sequences by point mutations in
he NS3 catalytic triad. A HCV NS3/4A construct containing human
BcAg (e.g. C8) was included as a control for comparison with
onstructs containing stork HBcAg. All fusion constructs had the
xpected size and cleavage pattern evidenced by results from an
n vitro transcription and translation assay (Fig. 1d). As shown previ-
usly in the in vitro transcription and translation assay, the cleavage
t NS3/4A junction sites was not complete whereby uncleaved
roducts are also visualized (Fig. 1d) [26,37]. On the other side,
onstructs containing 2A self-cleaving peptide sequences had an
lmost complete cleavage of NS3-NS4A and stork HBcAg shown by
nly a NS3 protein band and the absence of an NS3-NS4A fusion
rotein (Fig. 1d).
We next analyzed the expression of all fusion constructs by
ransient transfection and Western blot analysis. From previous
xperience we know that the NS3-NS4A cleavage is close to 100%
ffective, which is clearly shown in Fig. 1e where all NS3 or NS3/4A-
ontaining constructs shows only protein bands corresponding
o the NS3 protein. Hence, all generated fusion constructs were
xpressed and processed to the expected proteins.
.3. Fragmented stork HBcAg-sequences adjuvant priming of
otent NS3/4A-speciﬁc T cell responses in wild-type- and
S3/4A-Tg mice
We  next evaluated if we could improve the vaccine immuno-
enicity of our previously designed vaccine composed of a NS3/4A
ene fused with human HBcAg (e.g. C8, Fig. 1c) [26] by inclusion of
urine (m)  IL-12. We  have previously shown that mIL-12 improved
he HBV-speciﬁc T cell response after DNA-based immunization
27]. The addition of mIL-12 signiﬁcantly improved the induction of
FN--production in immunized NS3/4A-Tg mice and should there-
ore be considered for inclusion in the vaccine composition (Fig. 2a,
 < 0.001 (NS3-CTL and human HBcAg), area under the curve [AUC]
nd analysis of variance [ANOVA]). Thereafter, ﬁve NS3/4A and
tork or human HBcAg [48] fusion plasmids were evaluated in4 (2016) 2821–2833 2825
combination with mIL-12, delivered using the IVIN device followed
by in vivo ET, in wild-type- and NS3/4A-Tg mice to identify the most
immunogenic plasmid (Fig. 2b and c, and Supplementary Fig. 1a).
As the “golden standard”, we used the C8 plasmid (Figs. 1c, 2a–c,
and Supplementary Fig. 1a). In both wild-type- and NS3/4A-Tg
mice, the NS3/4A constructs with active protease and a fragmented
stork HBcAg (C2.2) induced the strongest immune responses deter-
mined by IFN-- and IL2-production (Fig. 2a–c, and Supplementary
Fig. 1a, p < 0.001 (NS3-CTL), AUC and ANOVA). Importantly, the use
of stork HBcAg even exceeded the immune activation to human
HBcAg (e.g. C8, p < 0.001 (NS3-CTL), AUC and ANOVA). Consistent
with previous data [26], the priming of T cells in NS3/4A-Tg
mice was  less efﬁcient due to the dysfunctional T cell response to
NS3/4A (Fig. 2c, and Supplementary Fig. 1b and c). This supports the
importance of the NS3/4A-Tg mouse model to dissect differences in
immunogenicity between NS3/4A-based vaccines. Quantiﬁcation
of NS3-speciﬁc CD8+ T-cells revealed similar frequencies of T cells
in wild-type mice regardless of the vaccine (Supplementary Fig.
1b and c, p = NS, Mann–Whitney U test). A single immunization
induced borderline levels of NS3-speciﬁc CD8+ T-cells determined
by pentamer staining in the NS3/4A-Tg mice (Supplementary Fig.
1b and c). Representative ﬂow cytometry dot plots have been
shown (Supplementary Fig. 1c). We  have previously shown that
the induction of low levels of NS3-speciﬁc CD8+ T-cells in the
NS3/4A-Tg mice requires at least two immunizations [26].
3.4. Co-expression of murine IL-12 improves immunogenicity to
NS3/4A
As mentioned in the previous section, one additional way  to
improve immunogenicity of genetic vaccines is the inclusion of
genetic adjuvants such as plasmids expressing cytokine genes for
example murine (m) IL-12 [27]. We  therefore tested whether the
addition of a mIL-12-expressing plasmid may  act as an adjuvant
for the vaccines containing NS3/4A and stork HBcAg (C2.2 and
C2.5; Fig. 1c). Mice were immunized intramuscularly once with
0.005, 0.05, 0.5, and 5 g of the NS3/4A-based plasmid contain-
ing stork HBcAg (C2.2), with or without, 5 g mIL-12 plasmid using
the in vivo intracellular injection (IVIN) device followed by in vivo
electro transfer (ET; Fig. 3a). The addition of IL-12 improved the
NS3-speciﬁc T cell response regardless of C2.2 vaccine dose (Fig. 3a,
p < 0.001 (NS3-CTL and E13K), AUC and ANOVA). Thus, addition of
IL-12 allowed for C2.2 vaccine doses as low as 0.05 g plasmid DNA
per dose resulting in detectable immune responses to NS3. Because
the vaccine is intended for human it is crucial that we develop a vac-
cine that is highly immunogenic also at low vaccine doses, making it
possible to translate the mouse vaccine dose into a realistic human
vaccine dose. Our data show that addition of IL-12 can help retain
the immunogenicity also at lower vaccine doses, which is impor-
tant when moving from smaller to larger animals and humans. To
test if this could be translated to other NS3/4A and stork HBcAg
genes, groups of wild-type mice were immunized intramuscularly
once with 0.5 g of either the C2.2 or C2.5 plasmid, together with
5 g mIL-12 using the IVIN device (Fig. 3b). Also the C2.5 plasmid
was highly immunogenic at the low 0.5 g dose in combination
with mIL-12 (Fig. 3b, p < 0.001 (NS3-CTL), and p < 0.01 (E13K), AUC
and ANOVA). Thus, the plasmid encoding mIL-12 was therefore
included in all further experiments.
3.5. Priming of NS3/4A-speciﬁc T cells in a host with
dysfunctional HBV-speciﬁc T cellsHBV is a common virus globally. One can therefore argue
whether the use of gene sequences from human HBV as carrier
molecules or adjuvants is advisable. Safety is one reason to use
non-human HBV sequences as adjuvants. We therefore immunized
2826 S. Levander et al. / Vaccine 34 (2016) 2821–2833
a) 
b) 
c) 
Fig. 2. T cell responses in wild-type- and NS3/4A-transgenic mice. Groups of ﬁve wild-type (e.g. C57BL/6J) and NS3/4A-transgenic mice were immunized once with 50 g
of  indicated NS3/4A-HBcAg plasmids in combination with 5 g mIL-12-pORF1 in a volume of 30 L by intramuscular immunization using the IVIN technology followed by
in  vivo ET. One group of mice were left untreated. Two weeks after immunization the mice were sacriﬁced and splenocytes harvested for determination of T cell responses.
A  comparison of the number of IFN- spot forming cells (SFCs) by ELISpot assay after stimulation with deescalating doses of either a CTL peptide (NS3-CTL, a; 0.25,
0.05,  0.01, 0.002, 0.0004 g/ml, b and c; 0.25, 0.025, 0.0025, 0.00025, 0.000025, 0.0000025, 0.00000025, 0.000000025 g/ml) and/or HBc-CTL (a; 2, 0.2, 0.02 g/ml), a Th
peptide (E13K, a; 2, 0.2, 0.02 g/ml, b and c; 10, 1, 0.1, 0.01, 0.001 g/ml) and/or HBc-Th (a; 2, 0.2, 0.02 g/ml), or a recombinant NS3 (rNS3) protein (10, 2, 0.4, 0.8, 0.016 g/ml)
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BeAg-Tg mice with a partially dysfunctional T cell response to
BcAg and HBeAg [27,33] with plasmids containing NS3/4A and
tork or human HBcAg (C2.2 and C8, respectively) or only human
BcAg. A single dose of NS3/4A and stork HBcAg seemed to prime
ower levels of NS3/4A-speciﬁc IFN-- and IL-2 in HBeAg-Tg mice
s compared to previous experiments in wild-type mice (Fig. 4a,
upplementary Fig. 2, and data not shown). Interestingly, the
tork containing NS3/4A plasmid primed signiﬁcantly stronger
FN--producing CTLs compared to the same plasmid containing
uman HBcAg (p < 0.05, AUC and ANOVA). As expected, similar
evels of NS3-speciﬁc CTLs were detected in C2.2 and C8 immu-
ized wild-type- and HBeAg-Tg mice (Fig. 4b and data not shown).
mportantly, the NS3/4A-stork HBcAg vaccine (C2.2) induced
igniﬁcantly lower levels of CTLs speciﬁc for human HBcAg, than
uman HBcAg alone (Fig. 4c). This is an important safety aspect
hen vaccinating against HCV in HBV infected individuals. Hence,
s predicted the use of stork HBcAg in the C2.2 plasmid avoided a
trong immune activation to human HBV in the HBeAg-Tg mice.
.6. Boosting effect of repeated immunization of NS3/4A
ontaining stork HBcAg
We  next investigated whether repeated immunization using
he plasmid containing NS3/4A and stork HBcAg construct (C2.2)
ad a booster effect. This is important because when the vaccine
s given to humans multiple doses will be needed for activation
f strong vaccine antigen-speciﬁc immune responses. Repeated
mmunizations will also answer whether a disadvantageous anti-
ector immune response is primed that will rapidly clear the
accine-antigen production at the site of immunization and sub-
equently result in a suboptimal booster effect. Immune responses
ere determined after one to ﬁve immunizations in wild-type-
nd NS3/4A-Tg mice. Wild-type- and NS3/4A-Tg mice were immu-
ized with 5 or 50 g plasmid, in combination with 5 g mIL-12
lasmid, using the IVIN device and in vivo ET. Repeated immun-
zations using either vaccine dose signiﬁcantly boosted both the
readth and magnitude of the NS3-speciﬁc T cell responses in
ild-type- and NS3/4A-Tg mice (Fig. 5a–c, and Supplementary Fig.
a–c, p < 0.001, p < 0.01, and p < 0.05, AUC and ANOVA). In partic-
lar the NS3-speciﬁc IL-2 responses were effectively boosted in
he wild-type mice (Fig. 5b, and Supplementary Fig. 3b). The use
f a higher vaccine dose (e.g. 50 g) seemed to prime stronger
mmune responses in the NS3/4A-Tg mice (Fig. 5c, and Supple-
entary Fig. 3c). Thus, NS3-speciﬁc T cell responses are boosted
y repeat immunizations in both wild-type- and NS3/4A-Tg mice.
.7. NS3/4A with stork HBcAg induces durable in vivo functional
mmune responses
To understand the duration of the primed immune responses
30,46] and key factors supporting durability, we  immunized wild-
ype, CD4−/−, and CD8−/− mice thrice with C2.2 in combination
ith mIL-12, using the IVIN device and in vivo ET. Long-term
urability of vaccine-primed immune responses is particularly
mportant for a prophylactic HCV vaccine. Here, vaccinated indi-
iduals should be protected even though exposed to infection at a
ater occasion. Of course, also in the case of a therapeutic vaccine
he durability of the primed immune response should be retained
ost-cure to reduce the risk of re-infection, but most importantly
as  done in immunized and non-immunized NS3/4A-transgenic (a and c) and wild-typ
VA-Th  (1 g/ml), OVA-protein (10 g/ml), and ConA (a; 2, 1, 0.5 g/ml, b and c; 2, 1, 0.5
epresents a speciﬁc concentration). Results are given as the mean SFCs/106 (+SD) with a
roup  that is signiﬁcantly different from all other groups (***p < 0.001, by comparing area4 (2016) 2821–2833 2827
be able to rapidly mediate clearance of the infected cells. We
showed that NS3-speciﬁc immune responses remain detectable
at six months after the third vaccination only in wild-type, and
not in CD4−/− or CD8−/− mice (Fig. 6a, and Supplementary Fig.
4, p < 0.001, AUC and ANOVA). Albeit the responses had reduced as
compared to two weeks after three immunizations (Figs. 5a and 6a),
they were still fully functional in vivo (Fig. 6b). This is of importance
in a prophylactic setting and in patients with a dysfunctional T
cell response [18–20,23]. Thus, although CD4+ T cells may  not
be pivotal during the priming of NS3-speciﬁc CTLs [51], they are
absolutely pivotal for the maintenance of the responses.
4. Discussion
Molecular adjuvants are often key components to improve
immunogenicity of vaccines. With respect to genetic vaccines, it
is optimal if the adjuvant can be produced at the same time as the
vaccine itself. Importantly, the adjuvant should be present in the
same cell as the vaccine to fully utilize its effects. Thus, in genetic
vaccines it is to be preferred that the adjuvant can be included in
the same expression vector as the vaccine genes.
It has previously been shown that human HBcAg can act as an
adjuvant for inserted sequences in the loop region (e.g. at the tip
of the spike) of HBcAg when expressed as a recombinant protein
[52–54]. HBcAg has been shown to have some unique properties
when used as a vaccine carrier or adjuvant. Hence, HBcAg is pre-
sented effectively through B-cells, which become activated through
crosslinking of surface receptors [55]. In addition, HBcAg binds RNA,
which activates toll-like receptor (TLR)-7 signaling [55]. Thus, these
properties make HBcAg an attractive adjuvant. We have shown that
HBcAg can be made highly immunogenic as a genetic immunogen,
and that human HBcAg can act as an adjuvant in genetic vaccines
[26]. However, there are concerns when using human HBcAg as
an adjuvant due to the fact that HBV is a common virus. In par-
ticular, the presence of a tolerized HBV-speciﬁc immune response,
or the activation of an HBV-speciﬁc immune response in a HBV
carrier may  have undesired and unexpected effects. This may  hold
true particularly when used in genetic immunogens that effectively
induce CTLs, which may  efﬁciently eradicate HBV infected hepato-
cytes and thereby cause fulminant hepatitis. Thus, it is important
to use safer adjuvants. This is where non-human, or avian, HBcAg
sequences come into play.
We  have shown that human HBcAg act as a genetic adjuvant, in
particular in supporting activation of NS3-speciﬁc T cell responses
in a host with a dysfunctional T cell response to HCV [26]. We
recently showed that human HBcAg could be made highly immuno-
genic on its own  with the addition of mIL-12 [27]. We  here wanted
to extend these two  observations to a completely new adjuvant
system.
We found that human, heron and stork HBcAg have a similar
intrinsic immunogenicity as DNA vaccines. Notably, they do
not share the same HLA/MHC class I and II epitope sequences,
which minimizes the risk of cross-reactivity between individ-
uals previously exposed to human HBV and possible recipients
of a genetic vaccine including stork HBcAg as adjuvant. This is
further strengthen by the fact that full-length human and avian
HBcAg show less than 40% amino acid sequence homology [48].
Importantly, we  could show that the immunogenicity of stork
HBcAg could be further improved by the addition of mIL-12 and
e C57BL/6J (b) mice. As control antigens OVA-CTL (a; 1 g/ml, b and c; 10 g/ml),
, 0.1 g/ml) were used. Deescalating doses are represented by triangles (each bar
 cut-off set at 50 SFCs/106 splenocytes. The statistical difference shown, indicate a
 under the curve (AUC) and analysis of variance (ANOVA)).
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a) 
b) 
Fig. 3. Co-administration of NS3/4A and IL-12 enhances the NS3-speciﬁc immune response. Groups of ﬁve wild-type C57BL/6J mice were immunized once with 0.005,
0.05,  0.5 and 5 g C2.2-pVAX1 plasmid DNA with or without 5 g mIL-12-pORF1 plasmid DNA in a volume of 30 L using IVIN followed by in vivo ET (a). One group of
mice  were left untreated (data not shown). Two weeks after immunization the mice were sacriﬁced and splenocytes harvested for determination of T cell responses. We
compared the number of IFN- SFCs by ELISpot assay after stimulation with deescalating doses of the following antigens: a CTL peptide (NS3-CTL, 0.25, 0.025, 0.0025, 0.00025,
0.000025, 0.0000025, 0.00000025, 0.000000025 g/ml), a Th peptide (E13K, 10, 1, 0.1, 0.01, 0.001 g/ml) or 9 peptide pools covering the full-length NS3 and NS4A proteins
(10,  1 g/ml). As control antigens OVA-CTL (1 g/ml), OVA-Th (1 g/ml), and ConA (1, 0.5 g/ml) were used. Deescalating doses are represented by triangles (each bar
represents a speciﬁc concentration). (b) Shows the number of IFN- SFCs in groups of mice immunized once with 0.5 g C2.2-pVAX or C2.5-pVAX1 in combination with 5 g
mIL-12-pORF1. Deescalating doses of exactly the same antigens as described in (a) were used for stimulation, except that we only used one concentration of the 9 peptide
pools  (10 g/ml). Results are given as the mean SFCs/106 (+SD) with a cut-off set at 50 SFCs/106 splenocytes. The statistical difference between the groups is indicated as
**p  < 0.01 and ***p < 0.001, area under the curve (AUC) and analysis of variance (ANOVA).
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Fig. 4. Addition of stork HBcAg improves the NS3-speciﬁc T cell response. Groups of HBeAg-transgenic mice (5 mice/group) were immunized once with 50 g of indicated
plasmids in combination with 5 g mIL-12-pORF1 in a volume of 30 L by intramuscular immunization using the IVIN technology followed by in vivo ET. One group of mice
were  left untreated. Two weeks after immunization the number of IFN- (a) SFCs after stimulation with deescalating doses of the following antigens: CTL peptides (NS3-CTL;
0.25,  0.025, 0.0025, 0.00025, 0.000025, 0.0000025, 0.00000025 g/ml HBc-CTL; 2, 0.2, 0.02 g/ml), Th peptides (E13 K; 10, 1, 0.1, 0.01, 0.001 g/ml, HBc-Th; 2, 0.2, 0.02 g/ml)
or  recombinant proteins (rNS3; 10, 2, 0.4, 0.8, 0.016 g/ml, rHBc; 10, 1, 0.1 g/ml) was  determined by ELISpot assay. As control antigens OVA-CTL (1 g/ml), OVA-Th (1 g/ml),
OVA-protein (10 g/ml), and ConA (1, 0.5 g/ml) were used. Deescalating doses are represented by triangles (each bar represents a speciﬁc concentration). Results are given
as  the mean SFCs/106 (+SD) with a cut-off set at 50 SFCs/106 splenocytes. Statistical differences have been indicated when one group of mice had signiﬁcantly higher levels
compared to all other groups (*p < 0.05, using area under the curve (AUC) and analysis of variance (ANOVA)). The expansion of NS3-speciﬁc (b) and HBcAg-speciﬁc (c) CD8+ T
cells  in HBeAg-transgenic mice was determined using direct ex vivo pentamer staining. GAVQNEVTL or MGLKFRQL epitope-speciﬁc CD8+ T cells are shown as the percentage
of  NS3- or HBcAg-pentamer positive CD8+ T cells where each ﬁlled black circle represent an individual mouse. The black horizontal line indicates the mean of the group. The
s rmine
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ltatistical difference between the groups is indicated as *p < 0.05 and **p < 0.01 dete
elivery by IVIN and in vivo ET. This enhanced immunogenicity
ould then be effectively transferred to HCV NS3/4A in various
usion constructs. Notably, we found that fragmented stork HBcAg
ore efﬁciently improved T cell priming to HCV NS3/4A than full-
ength stork HBcAg. Hence, this may  be a general aspect of HBcAgd by the Mann–Whitney U test.
regardless of the species as this also applied to human HBcAg [26].
This is possibly explained by the fact that HBcAg may provide
heterologous T cell help at the site of immunization and/or in
local lymphnodes thereby enhancing the priming of HCV-speciﬁc
T cell responses. However, the exact mechanism/s how stork
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Fig. 5. Repeated immunization improves the NS3-speciﬁc immune responses. Groups of wild-type C57BL/6J and NS3/4A-transgenic mice (5 mice/group) were immunized
one  to ﬁve times (e.g. 1×, 2×, 3×, 4×, 5×) with 50 g of the C2.2-pVAX1 plasmid in combination with 5 g mIL-12-pORF1 in a volume of 30 L using IVIN followed by in vivo
ET.  Two weeks after last immunization the mice were sacriﬁced and splenocytes harvested for determination of the number of IFN- SFCs in wild-type C57BL/6J (a) and
NS3/4A-transgenic (c) mice and IL-2 SFCs in wild-type C57BL/6J mice (b) by ELISpot assay. The production of IFN- and IL-2 was  determined after in vitro stimulation of
splenocytes with deescalating doses of the following antigens: a CTL peptide (NS3-CTL, 0.25, 0.025, 0.0025, 0.00025, 0.000025, 0.0000025, 0.00000025, 0.000000025 g/ml),
a  Th peptide (E13K, 10, 1, 0.1, 0.01, 0.001, 0.0001, 0.00001 g/ml) and a recombinant NS3 (rNS3, 10, 2, 0.4, 0.8, 0.016, 0.0032, 0.00064 g/ml) protein as indicated. As control
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Fig. 6. Priming of long-term duration of NS3-speciﬁc immune responses requires both CD4+ and CD8+ T cells. To evaluate the longevity of NS3-speciﬁc immune responses
groups of 8–10 wild-type C57BL/6J, CD4−/− and CD8−/− mice were immunized thrice at monthly intervals with 50 g C2.2-pVAX1 in combination with 5 g mIL-12-pORF1
in  a volume of 30 L using IVIN followed by in vivo ET. Also, groups of ﬁve wild-type C57BL/6J, CD4−/− and CD8−/− mice were left untreated. Six months after the last
immunization, mice were challenged using a hydrodynamic injection of 100 g coNS3/4A-pVAX1. 72 h later mice were sacriﬁced and splenocytes harvested for determination
of  IFN- responses (a) and livers for presence of hepatic NS3-protein in immunized and non-immunized groups (b). We compared the number of IFN- SFCs by ELISpot assay
after  stimulation with the following antigens: a CTL peptide (NS3-CTL, 0.25, 0.025, 0.0025, 0.00025, 0.000025, 0.0000025 g/ml), a Th peptide (E13K, 10, 1 g/ml) or 9 peptide
pools  covering the full-length NS3 and NS4A proteins (10, 1 g/ml). As control antigen ConA (2, 1 g/ml) was  used. Deescalating doses are represented by triangles (each bar
represents a speciﬁc concentration). Results are given as the mean SFCs/106 (+SD) with a cut-off set at 50 SFCs/106 splenocytes. Statistical differences have been evaluated
among groups of immunized mice and between immunized and non-immunized mice (***p < 0.001 using area under the curve (AUC) and analysis of variance (ANOVA), non-
immunized groups are shown in Supplementary Fig. 4). In vivo clearance of transient hepatic NS3-protein expression was analyzed by immune-precipitation and Western
blot  72 h after the hydrodynamic injection in groups of immunized- and non-immunized wild-type- and CD4 and CD8 knockout mice (b). A “+” indicate positive control (e.g.
coNS3/4A transiently transfected HepG2 cells), and a “−” indicate the negative control (e.g. mock transfected HepG2 cells). The number and percentage of NS3-positive mice
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BcAg enhances the HCV NS3/4A-speciﬁc T cell response has to
e determined. The HCV NS3/4A and stork HBcAg-based vaccines
ffectively primed HCV-speciﬁc CTLs without an effective induc-
ion of CTLs speciﬁc for human HBcAg. This is an essential safety
spect of any adjuvant system utilizing sequences from human
athogens.
The immunogenicity of the HCV NS3/4A and stork HBcAg-
ased vaccines could be boosted by giving additional monthly
accination. In particular the IL-2 producing T-helper cell
esponses improved after boosting, which is essential for T
ell expansion and memory development. We  could show that
hree doses of the C2.2 vaccine resulted in in vivo functional
ntigens OVA-CTL (1 g/ml), OVA-Th (1 g/ml), OVA-protein (10 g/ml), and ConA (2, 1
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he  curve (AUC) and analysis of variance (ANOVA)).ch group and additional data is included as data not shown. Statistical differences
sing Fischer’s exact test). NS = not signiﬁcant.
T cell responses that lasted for at least six months. This
aspect is essential in a prophylactic setting, where a T cell
based vaccine should rapidly mediate clearance of the invading
virus.
In conclusion, we  here show that avian HBcAg sequences effec-
tively and safely can be applied to genetic vaccines as molecular
adjuvants encoded by the same plasmid as the vaccine. This simpli-
ﬁes vaccine development. In addition, we have also shown that this
adjuvant effect can be applied to other viral vaccines (Holmström
et al., accepted for publication in Scientiﬁc Reports). Thus, avian
HBcAg can effectively be applied as a general adjuvant in genetic
vaccines.
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